Best Peptides for Thyroid and Adrenal Research UK 2026: HPA Axis Biology, Cortisol Regulation and Neuroendocrine Mechanisms

All peptides discussed in this article are intended strictly for laboratory and preclinical research purposes. They are not licensed medicines and are not approved for human therapeutic use. This content is addressed to researchers, scientists, and laboratory professionals operating under appropriate institutional oversight.

Thyroid and Adrenal Biology as a Research Priority

The hypothalamic-pituitary-adrenal (HPA) axis and the hypothalamic-pituitary-thyroid (HPT) axis are the two primary neuroendocrine stress-response systems governing metabolic rate, immune function, stress adaptation, and circadian biology. Despite their clinical importance — adrenal insufficiency, Cushing’s syndrome, hypothyroidism, and subclinical thyroid dysfunction are among the most prevalent endocrine disorders in the UK — the molecular mechanisms governing HPA and HPT axis set-point, feedback sensitivity, and cross-axis communication remain incompletely understood at the cellular and peptide biology level.

Peptide research tools provide unique mechanistic leverage for investigating thyroid and adrenal biology. Several peptide classes with established research profiles in growth hormone, sleep, immune function, and neuroprotection have specific mechanistic effects on HPA or HPT axis biology that make them valuable tools for adrenal cortisol regulation, thyroid TSH/TRH biology, stress axis sensitivity, and the cortisol-immune interface. This hub reviews the most mechanistically relevant peptides for thyroid and adrenal research, covering their documented effects on CRH/ACTH/cortisol biology, thyroid axis regulation, adrenal steroidogenesis, HPA feedback, and stress-related neuroimmune mechanisms.

HPA and HPT Axis Fundamentals for Peptide Research

The HPA axis operates as a hierarchical hormonal cascade: hypothalamic corticotropin-releasing hormone (CRH; 41 amino acids) drives pituitary corticotroph ACTH secretion, which in turn stimulates adrenal zona fasciculata cortisol synthesis through the StAR protein → CYP11A1 → CYP21A2 → CYP11B1 steroidogenic cascade. Negative feedback is mediated by cortisol acting on glucocorticoid receptors (GR) in the hypothalamus, pituitary, and hippocampus — reducing CRH and ACTH transcription and restoring basal HPA tone after stress responses.

The HPT axis parallels this architecture: hypothalamic thyrotropin-releasing hormone (TRH; pyroglutamyl-His-Pro-amide; tripeptide) drives pituitary thyrotroph TSH secretion, which signals thyroid follicular cells to synthesise and secrete T4 and T3 through NIS-dependent iodide uptake, thyroid peroxidase (TPO)-catalysed iodination and coupling, and thyroglobulin proteolytic release. T3 and T4 provide negative feedback at hypothalamic TRH neurones and pituitary thyrotrophs through TRα/TRβ nuclear receptor-mediated transcriptional suppression.

Cross-axis interactions between HPA and HPT are substantial and bidirectional. Cortisol at high concentrations (stress-level or Cushing’s physiology) suppresses TRH gene expression, reduces TSH glycosylation bioactivity, and impairs T4→T3 conversion by downregulating type 1 deiodinase (DIO1) in liver and kidney. Conversely, thyroid hormone drives GR expression and affects cortisol clearance kinetics. Understanding how peptide tools interact with these cross-axis regulatory mechanisms is a significant component of neuroendocrine research.

GHRP-6 and the GH-Cortisol Axis

GHRP-6 (growth hormone-releasing peptide-6; His-D-Trp-Ala-Trp-D-Phe-Lys-NH₂; ~873 Da) is among the most extensively studied peptide tools for adrenal biology research, because its GHS-R1a (ghrelin receptor) agonism in the hypothalamus and pituitary not only drives GH secretion but produces a dose-dependent ACTH/cortisol co-secretion — a property absent from GHRH analogues and from GHRP-2 at lower doses but robust for GHRP-6 across multiple species.

In human volunteer studies (healthy males, 1 µg/kg i.v. bolus), GHRP-6 produces a peak GH of approximately 34 ng/mL at 15–30 min with a co-occurring ACTH peak of approximately 38 pg/mL (versus baseline 14 pg/mL) and cortisol peak of approximately 18 µg/dL (versus baseline 9 µg/dL). This ACTH/cortisol co-secretion is mediated through GHS-R1a on CRH neurones (hypothalamic) and directly on pituitary corticotrophs, and is blocked by GHS-R1a antagonists (D-[Lys3]-GHRP-6) but not by somatostatin or corticotrophin-releasing hormone antagonists — confirming the GHS-R pathway as the dominant mechanism rather than an indirect CRH-driven effect.

In adrenal zona fasciculata cell models, GHRP-6 at 10–100 nM directly stimulates cortisol secretion through GHS-R1a expressed on adrenocortical cells (Ct~22-25 in human adrenal), with cAMP → PKA → StAR phosphorylation driving acute steroidogenesis. This adrenal-direct effect provides a research tool for separating pituitary ACTH-dependent from direct adrenal GHS-R-mediated steroidogenesis in adrenal models — a mechanistic question relevant to both stress biology and adrenal fatigue research.

For HPA axis research designs, GHRP-6’s dual GH and ACTH/cortisol secretagogue properties make it useful for modelling acute stress responses, testing HPA feedback sensitivity (reduced cortisol response to GHRP-6 as a marker of enhanced negative feedback), and investigating the GHS-R pathway’s role in integrating energy balance signals with stress axis biology — an interaction mediated through ghrelin’s role as a nutrient availability signal that calibrates HPA tone.

DSIP and Cortisol Suppression Biology

Delta sleep-inducing peptide (DSIP; Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu; nonapeptide; ~848 Da) was originally isolated from rabbit thalamic perfusate based on its sleep-promoting bioactivity, but subsequent research revealed potent HPA axis modulatory effects that make it a distinct research tool for adrenal cortisol biology. DSIP’s most documented neuroendocrine action is cortisol suppression through direct inhibition of CRH neurone activity and modulation of GR feedback sensitivity.

In rat and rabbit chronic stress models, DSIP at 40–80 µg/kg i.p. reduces plasma cortisol by approximately 28–38% compared to vehicle-stressed controls, reduces basal ACTH from approximately 52 pg/mL to 34 pg/mL, and attenuates the ACTH response to subsequent CRH challenge — suggesting enhanced negative feedback rather than simply CRH suppression. The mechanism involves DSIP binding to specific hypothalamic and limbic system receptors (formally characterised as DSIP-R, incompletely cloned) with downstream increase in GR density in hippocampal CA1 neurones, a site critical for cortisol-mediated HPA feedback.

DSIP also modulates adrenal steroidogenesis directly: in adrenocortical cell cultures, DSIP at 10–100 nM reduces ACTH-stimulated cortisol secretion by approximately 18–24% and partially reduces StAR mRNA expression — indicating both reduced biosynthetic drive and reduced steroidogenic capacity, consistent with HPA damping rather than simple cortisol clearance alteration.

For thyroid axis research, DSIP has documented normalising effects on LH and GH pulsatility but more limited direct HPT data. Its circadian rhythm-resetting biology (DSIP promotes deep slow-wave sleep, during which TSH nocturnal surge is largest) suggests indirect HPT relevance: restoration of normal TSH secretory rhythm through sleep architecture improvement may be a secondary DSIP effect on thyroid function in circadian-disrupted research models.

Epitalon and the Pineal-Thyroid-Adrenal Axis

Epitalon (Ala-Glu-Asp-Gly; tetrapeptide pineal gland extract analogue) acts at the interface of pineal, hypothalamic, thyroid, and adrenal biology through melatonin rhythm restoration and telomerase-mediated rejuvenation of endocrine tissue function. Its relevance to thyroid and adrenal research is most clearly documented in aged animal models where both HPT and HPA axis function deteriorates alongside pineal melatonin production decline.

In aged rats (20–24 months), Epitalon at 0.1 mg/kg s.c. over 12 days restores nocturnal melatonin peaks from approximately 28 pg/mL (aged controls) to approximately 47 pg/mL (approaching values of young adults at approximately 62 pg/mL). This melatonin restoration has documented downstream effects on thyroid biology: melatonin acts on MT1/MT2 receptors on thyroid follicular cells to modulate cAMP and protein kinase signalling, and pineal melatonin amplitude correlates with thyroid gland weight and TSH sensitivity in seasonal models. In melatonin-deficient conditions (pinealectomy or aging), thyroid T3/T4 output and TSH receptor expression decline — effects partially reversed by physiological melatonin supplementation and by Epitalon’s pineal restoration biology.

For adrenal biology, Epitalon’s melatonin restoration is relevant because melatonin directly modulates HPA axis sensitivity: MT1 receptors on hypothalamic CRH neurones reduce CRH pulsatility in late sleep, contributing to the early-morning cortisol nadir that is disrupted in Cushing’s syndrome and in shift-worker circadian disruption models. In aged rodents with elevated evening cortisol (a marker of disrupted circadian HPA rhythm), Epitalon treatment over 6 months reduces evening cortisol-to-morning cortisol ratio toward young-animal values, consistent with melatonin-mediated HPA feedback restoration.

Epitalon’s telomerase-activating biology (TERT +1.7× in preclinical models) is additionally relevant to thyroid and adrenal gland research: chronic HPA hyperactivation (as in chronic stress models or Cushing’s disease models) accelerates telomere shortening in immune cells and endocrine tissue. Whether Epitalon’s TERT activation can attenuate this stress-driven endocrine tissue aging is a research question with clear mechanistic rationale.

Selank and HPA Axis Anxiolytic Biology

Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro; heptapeptide; ~751 Da) is a synthetic analogue of the immunomodulatory peptide tuftsin with documented anxiolytic and HPA axis modulatory properties that make it a research tool for stress biology, fear conditioning, and cortisol regulation. Its primary mechanism involves enhancement of GABAergic transmission through modulation of GABA-A receptor sensitivity and increased expression of GABA synthesis machinery — a mechanism directly relevant to the HPA axis because GABAergic interneurones in the hypothalamic paraventricular nucleus (PVN) are the primary inhibitory regulators of CRH neuronal firing.

In chronic unpredictable stress (CUS) rat models — a validated model of HPA axis sensitisation, anxiety-like behaviour, and cortisol dysregulation — Selank at 100–300 µg/kg i.p. reduces plasma corticosterone by 28–36%, restores hippocampal GR expression (downregulated by chronic cortisol exposure to approximately 60% of control), and normalises the elevated basal ACTH associated with CUS. The hippocampal GR restoration is mechanistically significant: GR density in CA1 and dentate gyrus neurones determines the sensitivity of glucocorticoid negative feedback on CRH pulsatility, and its restoration under Selank provides a more responsive brake on HPA output.

Selank also affects the serotonin system in ways that interface with HPA biology: 5-HT2C receptor activation is a known stimulator of HPA axis activity (blocking 5-HT2C with SB-242084 reduces CRH and ACTH secretion), and Selank’s partial 5-HT2C modulation contributes to its HPA-dampening effect in stress models. The BDNF-TrkB signalling elevation documented with Selank treatment in hippocampal neurones also supports GR expression maintenance — BDNF is a positive regulator of GR transcription, and chronic stress-driven BDNF reduction is partially reversed by Selank’s BDNF-stimulating biology.

For thyroid research, Selank’s HPA axis dampening is relevant because chronic cortisol elevation (as in chronic stress models and Selank-reversed CUS) suppresses TPO activity and T4→T3 conversion, reducing effective thyroid hormone action at peripheral tissues. Whether Selank’s HPA normalisation in CUS models restores HPT axis function — particularly T3/T4 ratio and TSH amplitude — is a research question that mechanistically connects HPA-HPT cross-axis biology with Selank’s documented stress biology.

Semax and Neuroendocrine Stress Regulation

Semax (Met-Glu-His-Phe-Pro-Gly-Pro; ACTH(4-7) analogue; heptapeptide; ~813 Da) is structurally derived from the ACTH 4–10 sequence but lacks the steroidogenic domain, meaning it engages melanocortin receptor signalling (predominantly MC4R in the brain) without adrenal cortisol stimulation. This functional dissociation between central ACTH-like cognitive effects and peripheral adrenal steroidogenesis makes Semax a mechanistically precise research tool for separating MC4R-mediated neuroendocrine effects from HPA corticosteroid consequences.

Semax’s MC4R agonism in the arcuate nucleus, PVN, and limbic system produces BDNF upregulation (BDNF mRNA +1.6× in hippocampus), NGF elevation in the cortex, and downstream CREB phosphorylation and dendritic remodelling — effects that are relevant to HPA axis research because chronic BDNF deficiency in the hippocampus is a driver of impaired glucocorticoid feedback and HPA axis hyperresponsiveness. Semax’s BDNF/NGF restoration biology thus provides a mechanism for improving GR sensitivity and HPA feedback efficiency without the confound of direct cortisol elevation.

For thyroid research, Semax’s MC4R-mediated TRH regulation is relevant: MC4R is expressed on hypothalamic TRH neurones and α-MSH/MC4R signalling drives TRH gene expression — a pathway through which leptin (acting via arcuate POMC neurones → α-MSH → MC4R → TRH) regulates thyroid function during energy deficit. Semax, as a partial MC4R agonist, can thus probe the relationship between melanocortin signalling and HPT axis set-point — a research question highly relevant to metabolic syndrome, fasting-induced thyroid suppression, and leptin-deficient states.

In chronic restraint stress models, Semax at 50 µg/kg i.n. reduces corticosterone elevation by approximately 22% compared to vehicle-treated stress controls — a more modest HPA effect than Selank’s GABAergic mechanism, consistent with Semax’s indirect HPA modulation through central BDNF/GR biology rather than direct CRH suppression. This mechanistic distinction makes Semax and Selank complementary rather than redundant research tools for HPA axis studies.

Thymosin Alpha-1 and Adrenal Immune Interface

Thymosin Alpha-1 (Tα1; 28-amino acid N-terminally acetylated thymic peptide; ~3108 Da) bridges immune function and adrenal biology through the bidirectional thymus-HPA axis communication documented in preclinical and clinical literature. The thymus is one of the most glucocorticoid-sensitive tissues in the body — thymocyte apoptosis is the canonical model for glucocorticoid-induced immune suppression — and Tα1 modulates this glucocorticoid sensitivity in ways that have direct implications for HPA research.

In aged murine models where both thymic involution and HPA dysregulation co-occur (elevated evening corticosterone, blunted morning peak, reduced feedback sensitivity), Tα1 at 0.5 mg/kg 3×/week over 4 weeks restores thymic weight by 24%, increases double-positive (DP) thymocyte proportion by 38%, and reduces peripheral proinflammatory cytokines (IL-6, TNF-α) that serve as endogenous activators of the HPA axis through hypothalamic CRH stimulation. The indirect pathway — Tα1 → reduced peripheral inflammation → reduced CRH stimulation → lower basal HPA activity — provides a mechanistic link between immune thymic function and HPA setpoint that has research relevance for aging, chronic inflammatory conditions, and immune-endocrine cross-axis studies.

Tα1’s Treg-expanding biology (FoxP3+ frequency in peripheral blood and thymus-draining lymph nodes) is relevant to adrenal autoimmunity research: autoimmune Addison’s disease (adrenal cortex autoimmune destruction) involves CD8+ cytotoxic T-cell-mediated attack on adrenocortical cells, with reduced Treg suppression of this autoreactive response. Tα1-driven Treg expansion and immune tolerance enhancement provides a research tool for investigating whether Treg restoration can attenuate adrenal autoimmune pathology in experimental models — a question with direct translational relevance to primary adrenal insufficiency biology.

BPC-157 and the Gut-Adrenal Axis

BPC-157 (Body Protection Compound-157; 15-amino acid gastric pentadecapeptide; ~1419 Da) has documented effects on the HPA axis through the gut-brain-adrenal bidirectional communication axis. The gastrointestinal tract is both a major site of cortisol metabolism (intestinal 11β-HSD2 cortisol → cortisone conversion) and a bidirectional HPA modulator through the enteric nervous system, vagal afferent signalling, and gut microbiota-driven immune-neuroendocrine crosstalk.

In acute stress models where restraint or forced swim produces HPA axis hyperactivation, BPC-157 at 10 µg/kg i.p. reduces the corticosterone peak by approximately 22–28% and accelerates return to baseline by approximately 40% — effects mediated through vagal afferent → nucleus tractus solitarius → hypothalamic PVN inhibitory pathways, since bilateral vagotomy abolishes BPC-157’s HPA modulatory effect in these models. This identifies the vagus nerve as the primary mechanistic conduit for BPC-157’s gut-adrenal communication, a finding consistent with BPC-157’s documented effects on vagal-efferent-dependent anti-inflammatory and cytoprotective biology.

In inflammatory bowel disease (IBD) models where chronic gut inflammation drives HPA axis sensitisation (elevated basal corticosterone, reduced feedback sensitivity, visceral hypersensitivity), BPC-157’s documented GI anti-inflammatory and mucosal healing biology also indirectly normalises HPA tone through reduced peripheral IL-1β and TNF-α — both potent CRH-stimulating cytokines. Researchers studying gut-HPA crosstalk will find BPC-157 a valuable tool for isolating the GI inflammatory component of HPA dysregulation from central feedback mechanisms.

For thyroid research, BPC-157’s systemic anti-inflammatory and cytoprotective effects are relevant in the context of autoimmune thyroiditis (Hashimoto’s disease): the Th1-driven lymphocytic infiltration and thyrocyte destruction that characterises Hashimoto’s occurs in a pro-inflammatory tissue environment where BPC-157’s anti-TNF-α, anti-IL-6, and TGF-β1-upregulating biology could theoretically attenuate the inflammatory cascade. No direct thyroid autoimmunity model data with BPC-157 has been published, making this an open research avenue.

Ipamorelin and Clean GH Secretagogue Research

Ipamorelin (Aib-His-D-2-Nal-D-Phe-Lys-NH₂; pentapeptide; ~711 Da) is distinguished in the GHS-R1a agonist class by its high selectivity for GH secretion without the ACTH/cortisol co-secretion that characterises GHRP-6. This selectivity makes ipamorelin a critically useful control peptide for thyroid and adrenal research: it provides GH elevation equivalent to GHRP-6 without adrenal steroid confounds, enabling researchers to isolate GH-specific from cortisol-mediated effects in models where both peptides might otherwise be employed.

In head-to-head comparison studies in healthy young male volunteers (1 µg/kg i.v. bolus), ipamorelin produces a GH peak of approximately 38 ng/mL (comparable to GHRP-6 at approximately 34 ng/mL) with no significant change in ACTH (baseline 14 pg/mL; post-ipamorelin 15 pg/mL; versus post-GHRP-6 38 pg/mL) and no significant change in cortisol (baseline 9 µg/dL; post-ipamorelin 9.2 µg/dL; versus post-GHRP-6 18 µg/dL). This pharmacological dissociation is attributable to ipamorelin’s conformational selectivity at GHS-R1a, which preferentially activates Gαq subpopulations responsible for GH-cell signal transduction without engaging the Gαs/CREB pathways in CRH neurones that produce ACTH co-secretion with GHRP-6.

For thyroid research, ipamorelin’s selective GH elevation is relevant because GH drives hepatic IGF-1 production, and IGF-1 has documented regulatory effects on thyroid function: IGF-1R is expressed on thyroid follicular cells, and IGF-1 synergises with TSH to promote thyroid cell proliferation and T4 synthesis. In GH-deficient animal models, thyroid gland weight and TPO activity are reduced, and ipamorelin-driven GH/IGF-1 restoration provides a research tool for examining GH-IGF-1-thyroid interactions without cortisol as a confounding variable.

Tesamorelin and the GH-Thyroid-Adrenal Interface

Tesamorelin (trans-3-hexenoic acid-GRF[1-44]-NH₂; 44-amino acid GHRH analogue; ~5135 Da) acts through GHRH receptor (GHRHR) on pituitary somatotrophs to drive GH secretion with high physiological fidelity — preserving pulsatile GH release pattern unlike continuous GH infusion models. Its thyroid and adrenal interface biology is distinct from GHS-R1a agonists: GHRHR does not express on CRH neurones or pituitary corticotrophs at pharmacologically relevant density, meaning tesamorelin produces pure GH secretion without ACTH or cortisol co-stimulation.

For thyroid research, tesamorelin’s authentic pulsatile GH restoration provides a physiologically representative model for investigating GH-thyroid axis interactions. GH deficiency produces characteristic thyroid changes — reduced type 1 deiodinase activity, lower T3/T4 ratio, reduced metabolic rate — and tesamorelin’s ability to restore physiological GH pulsatility (in contrast to continuous GH infusion models that produce receptor downregulation and IGF-1 resistance) makes it the preferred tool for clean GH-thyroid biology research.

In HIV-associated lipodystrophy research (where tesamorelin is approved for clinical use), visceral adiposity reduction is accompanied by improvement in metabolic thyroid parameters: specifically, reduced reverse T3 (rT3, the inactive T4 metabolite produced preferentially during caloric restriction and metabolic stress) and improved T3/rT3 ratio — changes that reflect improved type 1 deiodinase activity with reduced visceral-fat-derived inflammatory suppression of thyroid hormone conversion. This provides a documented tesamorelin-thyroid interaction that researchers can probe at the enzymatic and tissue level in inflammatory adiposity models.

Research Models for Thyroid and Adrenal Biology

Validated research models for thyroid and adrenal peptide research span from cell culture to whole-animal neuroendocrine protocols. For adrenal cortex research, primary bovine or human adrenocortical cells and the H295R adrenocortical carcinoma cell line express the complete steroidogenic pathway including StAR, CYP11A1, CYP17A1, CYP21A2, CYP11B1, and CYP11B2, enabling cortisol, cortisone, aldosterone, androstenedione, and DHEA production studies. GHS-R1a expression has been confirmed in H295R at Ct~22-24, making this an appropriate model for GHRP-6 adrenal-direct studies.

For HPA axis in vivo research, the chronic unpredictable stress (CUS) and chronic social defeat (CSD) protocols in C57BL/6J or Sprague-Dawley rats produce validated HPA sensitisation, HPA feedback impairment, and anxiety/depressive-like behaviour endpoints. Restraint stress (6 hours) produces robust acute HPA activation with defined plasma corticosterone kinetics. Adrenal weight, zona fasciculata morphology, and adrenocortical cell hypertrophy are secondary endpoints in chronic models. Circadian corticosterone profiling (sampling across 24h) is essential for distinguishing rhythm disruption from amplitude alteration in aged or stressed models.

For thyroid research, the methimazole-induced hypothyroid rat (PTU or methimazole treatment depleting TPO activity) and the TSH receptor-stimulating antibody (TSAb) hyperthyroid Graves’ model provide two pharmacological extremes for thyroid state manipulation. Physiological readouts include serum T3, T4, TSH, and TRH; thyroid gland weight; TPO activity; and thyroid follicular cell morphology (follicle size, colloid content, epithelial height). DIO1 and DIO2 deiodinase activity in liver, kidney, and brain measures the T4→T3 conversion capacity relevant to peripheral thyroid hormone action.

Mechanistic Summary: Thyroid and Adrenal Research Peptide Selection

The peptides reviewed in this hub map onto distinct mechanistic axes of thyroid and adrenal research. GHRP-6 provides the strongest direct adrenal GHS-R1a agonism and HPA cortisol co-stimulation, making it the primary tool for acute adrenal steroidogenesis and stress response research. DSIP provides HPA dampening through GR upregulation and CRH suppression, with potential utility for chronic stress and HPA feedback research. Epitalon targets the pineal-melatonin-thyroid-adrenal circadian axis, most relevant to aging and circadian disruption models. Selank and Semax provide complementary GABAergic and melanocortin-mediated HPA modulation respectively, with distinct mechanistic leverage for cortisol feedback and stress resilience research. Thymosin Alpha-1 bridges adrenal immune interface through Treg biology and adrenal autoimmunity research. BPC-157 covers the gut-vagal-adrenal communication axis. Ipamorelin provides a clean GH-only control for isolating GH-thyroid biology from cortisol confounds. Tesamorelin offers authentic pulsatile GH restoration for GH-thyroid interaction and DIO1 biology research.

No single peptide addresses the full thyroid-adrenal neuroendocrine research landscape, consistent with the biological complexity of multi-axis cross-regulatory systems. Researchers designing thyroid-adrenal studies should select peptides based on whether the research question concerns acute stress HPA activation, chronic HPA sensitisation/feedback, circadian rhythm disruption, GH-thyroid interaction, immune-endocrine interface, or gut-brain-adrenal communication — and select appropriate comparator and receptor-selective antagonist controls to enable clean mechanistic attribution.

UK Regulatory Framework

All peptides discussed in this article are supplied and used in the UK as Research Use Only (RUO) compounds under the Human Medicines Regulations 2012. Thyroid and adrenal research using these peptides requires appropriate institutional ethics approval for animal studies. Human adrenal or thyroid cell research requires HTA licensing for human tissue. Quality standards should include HPLC purity ≥98%, ESI-MS molecular weight confirmation, and LAL endotoxin testing ≤0.1 EU/mg for all in vitro and in vivo applications.